Does the media refer more to SRPT or CTMX?

In the previous week, Sarepta Therapeutics had 9 more articles in the media than CytomX Therapeutics. MarketBeat recorded 13 mentions for Sarepta Therapeutics and 4 mentions for CytomX Therapeutics. CytomX Therapeutics' average media sentiment score of 1.45 beat Sarepta Therapeutics' score of 0.60 indicating that CytomX Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sarepta Therapeutics 5 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive CytomX Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer SRPT or EDIT?

In the previous week, Editas Medicine had 1 more articles in the media than Sarepta Therapeutics. MarketBeat recorded 14 mentions for Editas Medicine and 13 mentions for Sarepta Therapeutics. Editas Medicine's average media sentiment score of 0.62 beat Sarepta Therapeutics' score of 0.60 indicating that Editas Medicine is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sarepta Therapeutics 5 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Editas Medicine 6 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor SRPT or PTGX?

In the previous week, Sarepta Therapeutics had 1 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 13 mentions for Sarepta Therapeutics and 12 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 0.61 beat Sarepta Therapeutics' score of 0.60 indicating that Protagonist Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sarepta Therapeutics 5 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Protagonist Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer SRPT or PCVX?

In the previous week, Vaxcyte had 3 more articles in the media than Sarepta Therapeutics. MarketBeat recorded 16 mentions for Vaxcyte and 13 mentions for Sarepta Therapeutics. Vaxcyte's average media sentiment score of 0.85 beat Sarepta Therapeutics' score of 0.60 indicating that Vaxcyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sarepta Therapeutics 5 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Vaxcyte 7 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer SRPT or CYTK?

In the previous week, Sarepta Therapeutics had 4 more articles in the media than Cytokinetics. MarketBeat recorded 13 mentions for Sarepta Therapeutics and 9 mentions for Cytokinetics. Cytokinetics' average media sentiment score of 0.90 beat Sarepta Therapeutics' score of 0.60 indicating that Cytokinetics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sarepta Therapeutics 5 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Cytokinetics 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Sarepta Therapeutics (SRPT) Competitors

$20.45 -0.07 (-0.34%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$19.92 -0.53 (-2.59%)

As of 09/11/2026 07:58 PM Eastern

Compare

SRPT vs. CTMX, EDIT, PTGX, PCVX, and CYTK

Should you buy Sarepta Therapeutics stock or one of its competitors? Sarepta Therapeutics's main competitors and comparable companies include CytomX Therapeutics (CTMX), Editas Medicine (EDIT), Protagonist Therapeutics (PTGX), Vaxcyte (PCVX), and Cytokinetics (CYTK). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Sarepta Therapeutics compare to CytomX Therapeutics?

Sarepta Therapeutics (NASDAQ:SRPT) and CytomX Therapeutics (NASDAQ:CTMX) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, earnings, dividends, analyst recommendations, institutional ownership and valuation.

Sarepta Therapeutics has a beta of 0.27, meaning that its share price is 73% less volatile than the broader market. Comparatively, CytomX Therapeutics has a beta of 2.14, meaning that its share price is 114% more volatile than the broader market.

Sarepta Therapeutics has a net margin of -13.48% compared to CytomX Therapeutics' net margin of -435.21%. Sarepta Therapeutics' return on equity of -1.60% beat CytomX Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sarepta Therapeutics	-13.48%	-1.60%	-0.66%
CytomX Therapeutics	-435.21%	-38.46%	-30.33%

Sarepta Therapeutics currently has a consensus target price of $25.69, indicating a potential upside of 25.61%. CytomX Therapeutics has a consensus target price of $11.90, indicating a potential upside of 261.70%. Given CytomX Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe CytomX Therapeutics is more favorable than Sarepta Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sarepta Therapeutics	6 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.15
CytomX Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

CytomX Therapeutics has lower revenue, but higher earnings than Sarepta Therapeutics. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than CytomX Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sarepta Therapeutics	$2.20B	0.98	-$713.41M	-$2.90	N/A
CytomX Therapeutics	$76.20M	9.41	-$17.37M	-$0.50	N/A

86.7% of Sarepta Therapeutics shares are held by institutional investors. Comparatively, 67.8% of CytomX Therapeutics shares are held by institutional investors. 6.9% of Sarepta Therapeutics shares are held by insiders. Comparatively, 3.8% of CytomX Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Sarepta Therapeutics had 9 more articles in the media than CytomX Therapeutics. MarketBeat recorded 13 mentions for Sarepta Therapeutics and 4 mentions for CytomX Therapeutics. CytomX Therapeutics' average media sentiment score of 1.45 beat Sarepta Therapeutics' score of 0.60 indicating that CytomX Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sarepta Therapeutics	5 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
CytomX Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

CytomX Therapeutics beats Sarepta Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Sarepta Therapeutics compare to Editas Medicine?

Sarepta Therapeutics (NASDAQ:SRPT) and Editas Medicine (NASDAQ:EDIT) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, analyst recommendations, earnings, risk, valuation, profitability and institutional ownership.

Sarepta Therapeutics has a beta of 0.27, indicating that its share price is 73% less volatile than the broader market. Comparatively, Editas Medicine has a beta of 2.09, indicating that its share price is 109% more volatile than the broader market.

Editas Medicine has lower revenue, but higher earnings than Sarepta Therapeutics. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sarepta Therapeutics	$2.20B	0.98	-$713.41M	-$2.90	N/A
Editas Medicine	$40.52M	10.23	-$160.06M	-$0.75	N/A

86.7% of Sarepta Therapeutics shares are owned by institutional investors. Comparatively, 71.9% of Editas Medicine shares are owned by institutional investors. 6.9% of Sarepta Therapeutics shares are owned by insiders. Comparatively, 3.1% of Editas Medicine shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Editas Medicine had 1 more articles in the media than Sarepta Therapeutics. MarketBeat recorded 14 mentions for Editas Medicine and 13 mentions for Sarepta Therapeutics. Editas Medicine's average media sentiment score of 0.62 beat Sarepta Therapeutics' score of 0.60 indicating that Editas Medicine is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sarepta Therapeutics	5 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Editas Medicine	6 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Sarepta Therapeutics currently has a consensus target price of $25.69, indicating a potential upside of 25.61%. Editas Medicine has a consensus target price of $6.00, indicating a potential upside of 122.22%. Given Editas Medicine's stronger consensus rating and higher possible upside, analysts plainly believe Editas Medicine is more favorable than Sarepta Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sarepta Therapeutics	6 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.15
Editas Medicine	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Sarepta Therapeutics has a net margin of -13.48% compared to Editas Medicine's net margin of -157.32%. Sarepta Therapeutics' return on equity of -1.60% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sarepta Therapeutics	-13.48%	-1.60%	-0.66%
Editas Medicine	-157.32%	-196.63%	-38.17%

Summary

Editas Medicine beats Sarepta Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Sarepta Therapeutics compare to Protagonist Therapeutics?

Sarepta Therapeutics (NASDAQ:SRPT) and Protagonist Therapeutics (NASDAQ:PTGX) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

86.7% of Sarepta Therapeutics shares are owned by institutional investors. Comparatively, 98.6% of Protagonist Therapeutics shares are owned by institutional investors. 6.9% of Sarepta Therapeutics shares are owned by company insiders. Comparatively, 5.2% of Protagonist Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Protagonist Therapeutics has a net margin of 29.40% compared to Sarepta Therapeutics' net margin of -13.48%. Protagonist Therapeutics' return on equity of 12.03% beat Sarepta Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sarepta Therapeutics	-13.48%	-1.60%	-0.66%
Protagonist Therapeutics	29.40%	12.03%	11.23%

Sarepta Therapeutics has a beta of 0.27, indicating that its share price is 73% less volatile than the broader market. Comparatively, Protagonist Therapeutics has a beta of 1.8, indicating that its share price is 80% more volatile than the broader market.

Protagonist Therapeutics has lower revenue, but higher earnings than Sarepta Therapeutics. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sarepta Therapeutics	$2.20B	0.98	-$713.41M	-$2.90	N/A
Protagonist Therapeutics	$46.02M	208.36	-$130.15M	$1.03	143.86

In the previous week, Sarepta Therapeutics had 1 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 13 mentions for Sarepta Therapeutics and 12 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 0.61 beat Sarepta Therapeutics' score of 0.60 indicating that Protagonist Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sarepta Therapeutics	5 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Protagonist Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Sarepta Therapeutics presently has a consensus price target of $25.69, suggesting a potential upside of 25.61%. Protagonist Therapeutics has a consensus price target of $147.13, suggesting a potential downside of 0.71%. Given Sarepta Therapeutics' higher possible upside, equities analysts clearly believe Sarepta Therapeutics is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sarepta Therapeutics	6 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.15
Protagonist Therapeutics	0 Sell rating(s)	2 Hold rating(s)	16 Buy rating(s)	0 Strong Buy rating(s)	2.89

Summary

Protagonist Therapeutics beats Sarepta Therapeutics on 12 of the 16 factors compared between the two stocks.

How does Sarepta Therapeutics compare to Vaxcyte?

Sarepta Therapeutics (NASDAQ:SRPT) and Vaxcyte (NASDAQ:PCVX) are both mid-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability, media sentiment and analyst recommendations.

Sarepta Therapeutics presently has a consensus price target of $25.69, suggesting a potential upside of 25.61%. Vaxcyte has a consensus price target of $98.00, suggesting a potential upside of 64.79%. Given Vaxcyte's stronger consensus rating and higher possible upside, analysts plainly believe Vaxcyte is more favorable than Sarepta Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sarepta Therapeutics	6 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.15
Vaxcyte	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

86.7% of Sarepta Therapeutics shares are owned by institutional investors. Comparatively, 96.8% of Vaxcyte shares are owned by institutional investors. 6.9% of Sarepta Therapeutics shares are owned by company insiders. Comparatively, 3.3% of Vaxcyte shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Sarepta Therapeutics has a beta of 0.27, suggesting that its share price is 73% less volatile than the broader market. Comparatively, Vaxcyte has a beta of 1.22, suggesting that its share price is 22% more volatile than the broader market.

In the previous week, Vaxcyte had 3 more articles in the media than Sarepta Therapeutics. MarketBeat recorded 16 mentions for Vaxcyte and 13 mentions for Sarepta Therapeutics. Vaxcyte's average media sentiment score of 0.85 beat Sarepta Therapeutics' score of 0.60 indicating that Vaxcyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sarepta Therapeutics	5 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Vaxcyte	7 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Sarepta Therapeutics has higher revenue and earnings than Vaxcyte. Vaxcyte is trading at a lower price-to-earnings ratio than Sarepta Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sarepta Therapeutics	$2.20B	0.98	-$713.41M	-$2.90	N/A
Vaxcyte	N/A	N/A	-$766.63M	-$7.63	N/A

Vaxcyte has a net margin of 0.00% compared to Sarepta Therapeutics' net margin of -13.48%. Sarepta Therapeutics' return on equity of -1.60% beat Vaxcyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sarepta Therapeutics	-13.48%	-1.60%	-0.66%
Vaxcyte	N/A	-37.56%	-33.62%

Summary

Sarepta Therapeutics beats Vaxcyte on 8 of the 15 factors compared between the two stocks.

How does Sarepta Therapeutics compare to Cytokinetics?

Sarepta Therapeutics (NASDAQ:SRPT) and Cytokinetics (NASDAQ:CYTK) are both mid-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, valuation, institutional ownership, profitability and analyst recommendations.

Sarepta Therapeutics has higher revenue and earnings than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than Sarepta Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sarepta Therapeutics	$2.20B	0.98	-$713.41M	-$2.90	N/A
Cytokinetics	$67.67M	135.65	-$784.96M	-$7.22	N/A

Sarepta Therapeutics has a beta of 0.27, suggesting that its share price is 73% less volatile than the broader market. Comparatively, Cytokinetics has a beta of 0.36, suggesting that its share price is 64% less volatile than the broader market.

Sarepta Therapeutics currently has a consensus target price of $25.69, suggesting a potential upside of 25.61%. Cytokinetics has a consensus target price of $103.37, suggesting a potential upside of 40.12%. Given Cytokinetics' stronger consensus rating and higher probable upside, analysts clearly believe Cytokinetics is more favorable than Sarepta Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sarepta Therapeutics	6 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.15
Cytokinetics	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	0 Strong Buy rating(s)	2.85

Sarepta Therapeutics has a net margin of -13.48% compared to Cytokinetics' net margin of -1,321.12%. Cytokinetics' return on equity of 0.00% beat Sarepta Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sarepta Therapeutics	-13.48%	-1.60%	-0.66%
Cytokinetics	-1,321.12%	N/A	-51.01%

86.7% of Sarepta Therapeutics shares are owned by institutional investors. 6.9% of Sarepta Therapeutics shares are owned by insiders. Comparatively, 2.6% of Cytokinetics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Sarepta Therapeutics had 4 more articles in the media than Cytokinetics. MarketBeat recorded 13 mentions for Sarepta Therapeutics and 9 mentions for Cytokinetics. Cytokinetics' average media sentiment score of 0.90 beat Sarepta Therapeutics' score of 0.60 indicating that Cytokinetics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sarepta Therapeutics	5 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Cytokinetics	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Sarepta Therapeutics beats Cytokinetics on 9 of the 16 factors compared between the two stocks.

Get Sarepta Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SRPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SRPT vs. The Competition

Export

Metric	Sarepta Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.17B	$3.86B	$7.15B	$12.71B
Dividend Yield	N/A	3.63%	2.56%	11.16%
P/E Ratio	-7.05	14.11	272.98	25.27
Price / Sales	0.98	1,415.79	642.14	88.20
Price / Cash	N/A	106.68	77.04	51.44
Price / Book	1.88	15.13	10.33	6.20
Net Income	-$713.41M	-$22.82M	$3.49B	$358.27M
7 Day Performance	-9.11%	-4.31%	-3.33%	-2.36%
1 Month Performance	11.26%	0.00%	-0.40%	-2.77%
1 Year Performance	17.60%	40.67%	19.15%	7.64%

Sarepta Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SRPT Sarepta Therapeutics	3.5789 of 5 stars	$20.45 -0.3%	$25.69 +25.6%	+14.2%	$2.17B	$2.20B	N/A	835	Analyst Upgrade
CTMX CytomX Therapeutics	2.8838 of 5 stars	$3.71 flat	$11.90 +220.8%	+57.4%	$808.41M	$76.20M	N/A	170	Positive News
EDIT Editas Medicine	2.2648 of 5 stars	$3.23 flat	$6.00 +85.8%	-0.4%	$496.06M	$40.52M	N/A	230	News Coverage
PTGX Protagonist Therapeutics	1.5544 of 5 stars	$145.72 flat	$147.13 +1.0%	+148.3%	$9.43B	$46.02M	141.48	120	Insider Trade
PCVX Vaxcyte	2.1854 of 5 stars	$61.16 flat	$86.00 +40.6%	+79.9%	$9.10B	N/A	N/A	160	Options Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SRPT) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sarepta Therapeutics (SRPT) Competitors

SRPT vs. CTMX, EDIT, PTGX, PCVX, and CYTK

How does Sarepta Therapeutics compare to CytomX Therapeutics?

Summary

How does Sarepta Therapeutics compare to Editas Medicine?

Summary

How does Sarepta Therapeutics compare to Protagonist Therapeutics?

Summary

How does Sarepta Therapeutics compare to Vaxcyte?

Summary

How does Sarepta Therapeutics compare to Cytokinetics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SRPT vs. The Competition

Sarepta Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sarepta Therapeutics (SRPT) Competitors

SRPT vs. CTMX, EDIT, PTGX, PCVX, and CYTK

How does Sarepta Therapeutics compare to CytomX Therapeutics?

Which has more volatility & risk, SRPT or CTMX?

Is SRPT or CTMX more profitable?

Do analysts prefer SRPT or CTMX?

Which has preferable earnings and valuation, SRPT or CTMX?

Do insiders and institutionals believe in SRPT or CTMX?

Does the media refer more to SRPT or CTMX?

Summary

How does Sarepta Therapeutics compare to Editas Medicine?

Which has more volatility and risk, SRPT or EDIT?

Which has preferable valuation and earnings, SRPT or EDIT?

Do insiders & institutionals hold more shares of SRPT or EDIT?

Does the media prefer SRPT or EDIT?

Do analysts prefer SRPT or EDIT?

Is SRPT or EDIT more profitable?

Summary

How does Sarepta Therapeutics compare to Protagonist Therapeutics?

Do insiders and institutionals have more ownership in SRPT or PTGX?

Is SRPT or PTGX more profitable?

Which has more volatility and risk, SRPT or PTGX?

Which has better valuation & earnings, SRPT or PTGX?

Does the media favor SRPT or PTGX?

Do analysts recommend SRPT or PTGX?

Summary

How does Sarepta Therapeutics compare to Vaxcyte?

Do analysts recommend SRPT or PCVX?

Do insiders & institutionals have more ownership in SRPT or PCVX?

Which has more volatility & risk, SRPT or PCVX?

Does the media prefer SRPT or PCVX?

Which has better valuation & earnings, SRPT or PCVX?

Is SRPT or PCVX more profitable?

Summary

How does Sarepta Therapeutics compare to Cytokinetics?

Which has higher earnings and valuation, SRPT or CYTK?

Which has more risk and volatility, SRPT or CYTK?

Do analysts recommend SRPT or CYTK?

Is SRPT or CYTK more profitable?

Do insiders and institutionals have more ownership in SRPT or CYTK?

Does the media prefer SRPT or CYTK?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SRPT vs. The Competition

Sarepta Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools